Influenza B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Influenza B Market Outlook

Thelansis’s “Influenza B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Influenza B Overview

Influenza B is a prevalent respiratory infection. Approximately 20-30% of diagnosed cases of influenza viral infections can be attributed to the influenza B virus. Similar to the influenza A virus, the influenza B virus belongs to the family Orthomyxoviridae. Both viruses possess segments 1, 3, 4, and 5, denoted as FLUA and FLUB, which encode a single protein per segment: PB2, PA, HA, and NP proteins. However, there are a few notable distinctions in influenza B viruses. For instance, segment 2 of FLUAV encodes the polymerase subunit PB1. In certain strains, this segment may also encode a small accessory protein called PB1-F2, which exhibits apoptotic activity. Influenza B viruses are classified into two lineages: B/Yamagata and B/Victoria. Additionally, IFB viruses are further categorized into specific clades and sub-clades. The B/Victoria clades encompass V1A, while the subclades consist of V1A.1, V1A.2, and V1A.3. The B/Yamagata clades encompass Y1, Y2, and Y3, without any subclades. IFB infections can manifest in various ways, such as croup, bronchiolitis, pneumonia, and febrile illness, which can mimic bacterial sepsis. Moreover, complications can arise affecting the central nervous system, heart, muscles, or kidneys. The most common presentation of IFB is a respiratory infection characterized by cough, fever, myalgia, chills, and malaise. The illness typically spans two to eight days, with a rapid onset A minority of patients, especially young children and those with medical comorbidities, may have a severe form. The prognosis for children affected by IFB is generally favorable. Hospitalization may be required for two to eight days in some cases.

• According to estimates, the United States has faced a considerable burden of influenza, with around 9 million cases of flu, 4 million flu-related medical visits, 100,000 hospitalizations, and approximately 5,000 deaths.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: